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A series of 14β-acyl substituted 17-cyclopropylmethyl-7,8-dihydronoroxymorphinone
compounds has been synthesized and evaluated for affinity and efficacy for mu (MOP),
kappa (KOP), and delta (DOP) opioid receptors and nociceptin/orphanin FQ peptide
(NOP) receptors. The majority of the new ligands displayed high binding affinities for
the three opioid receptors, and moderate affinity for NOP receptors. The affinities for
NOP receptors are of particular interest as most classical opioid ligands do not bind to
NOP receptors. The predominant activity in the [35S]GTPγS assay was partial agonism
at each receptor. The results are consistent with our prediction that an appropriate 14β
side chain would access a binding site within the NOP receptor and result in substantially
higher affinity than displayed by the parent compound naltrexone. Molecular modeling
studies, utilizing the recently reported structure of the NOP receptor, are also consistent
with this interpretation.
Keywords: opioid, nociceptin, ORL-1, analgesics, kappa opioid receptor, mu opioid receptors
INTRODUCTION
There are three classical opioid receptors mu (MOP), delta (DOP), and kappa (KOP), which
play important physiological and pharmacological roles especially in pain regulation. In addition
to these, the NOP receptor (earlier ORL1) was identified as a fourth member of the opioid
receptor family. This G-protein coupled receptor (1) has significant homology with classical
opioid receptors; however none of the endogenous opioid ligands show high affinity to NOP.
The endogenous ligand for this receptor, nociceptin/orphanin FQ (N/OFQ) (2, 3) is a 17 amino
acid peptide having sequence similarity to the opioid peptides, particularly dynorphin, but it itself
does not have high affinity for other opioid receptors. Various early studies indicated that the NOP
receptor may play an important role in pain regulation (4), the cardiovascular system (5, 6), opioid
tolerance (7), learning andmemory (8–10), anorexia (11), anxiety (12), and others (6). However, the
development of new therapeutics targeting NOP receptors has not proven easy and it has become
clear that the biological actions of NOP receptor ligands vary enormously depending on species,
route of administration and dose (13).
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For example, the pharmacological action of nociceptin on
the perception of pain is not straightforward. Early studies on
nociceptin provided mutually contradictory results of either
increasing or decreasing perception of pain, depending on dose,
site and method of administration (14, 15). Whereas Meunier
et al. (3) reported nociceptin induced hyperalgesia in the hot
plate test when injected intracerebroventricularly (i.c.v) in mice,
Rossi et al. (16) found that i.c.v nociceptin produced a transient
hyperalgesia followed by analgesia in the tail flick test in mice.
More recent evidence from studies using non-human primates,
which may have greater translational validity than studies using
rodents, appears to confirm that NOP agonists have analgesic
effects comparable to morphine (17–19), though variations in
level of response have been reported (20).
Often medicinal chemistry programs aim to develop ligands
with ever greater selectivity for a particular target so as to
decrease the possibility of side effects. More recently there has
been a move to rationally design drugs having a multi receptor
affinity profile, recognizing the complexity of many disease
states (21, 22). The continued development of Cebranopadol,
now in multiple clinical trials is an example of this approach
(23, 24). Cebranopadol is a potent, full agonist at both MOP
and NOP receptors but is reported to have an improved safety
profile over standard MOP receptor agonist analgesics. In a
similar vein our groups have been interested in the development
of compounds with a mixed affinity profile, including MOP
partial agonist/NOP receptor partial agonists and separately
MOP partial agonist/KOP partial agonists (25–27). In particular,
MOP/NOP partial agonists are expected to be analgesic but with
reduced side effect profile, including less respiratory depression,
low abuse potential and less tolerance development (27–30).
The orvinol, buprenorphine (1) is a partial MOP receptor
agonist with modest affinity for the NOP receptor (31). Its
efficacy in the treatment of pain may involve a NOP receptor
component (32). The close homolog of buprenorphine, BU08028
(2) (26, 27), displays significant affinity and partial agonist
activity for NOP receptors in vitro and SAR from this series
of orvinols provides evidence that the region of space occupied
by the t-butyl group in buprenorphine is key to good NOP
receptor activity (26). Subsequently, similar NOP activity was
found in the related phenethyl orvinols (3) (33) further
highlighting the importance of the C20 group in the orvinol
series.
The 14β-hydroxymorphinan-6-ones naltrexone (4) and
naloxone are MOP receptor antagonists used in clinical practice.
It is known that substituting the C14-oxygen can have a dramatic
effect on the opioid receptor profile of these compounds
(34, 35). Thus, while 14-O methyl & ethyl derivatives (36, 37)
of naltrexone and naloxone are nonselective opioid receptor
antagonists, 14-phenylpropyloxymorphinan-6-ones (38) have
shown powerful agonist properties. We have previously reported
Abbreviations: MOP receptor, mu opioid receptor; NOP receptor,
nociceptin/orphanin FQ receptor; DOP receptor, delta opioid receptor; KOP
receptor, kappa opioid receptor; MPE, maximum percent effect; ANOVA,
analysis of variance; DAMGO, [D-Ala2, N-MePhe4, Gly-ol]-enkephalin; DPDPE,
[D-Pen2,D-Pen5]enkephalin.
on cinnamoyl esters of naltrexone as MOP receptor antagonists-
partial agonists (39). From molecular modeling studies, it is
clear that a suitable substituent attached to the C14-oxygen of
naltrexone could access the same region of space as the t-butyl
group of buprenorphine and it therefore seemed possible that
such a series of ligands might display the mixed MOP/NOP
receptor partial agonist activity desired.
CHEMISTRY
The 3-hydroxy group of 4 was protected with tert-
butyldimethylsilyl chloride in order to carry out selective
esterification of the 14-hydroxy group. The tendency of the C6-
carbonyl to exist in its enol form meant that clean esterification
was not possible with acyl chlorides but could be achieved with
the appropriate anhydrides which were synthesized from the
corresponding phenylacetic acid and triphosgene. Thereafter
the 3-hydroxy group was regenerated using a 1:1 mixture of
methanol and HCl (6N) to give the target esters (7) (Scheme 1).
RESULTS
Affinities for the individual opioid receptors were determined
in displacement binding assays in recombinant human opioid
receptors transfected into Chinese hamster ovary (CHO) cells
as previously described (31). The displaced selective radioligands
were [3H]N/OFQ (NOP), [3H]DAMGO (MOP), [3H]Cl-DPDPE
(DOP), and [3H]U69593 (KOP). All of the ligands displayed
high affinity binding in the subnanomolar to nanomolar range
toward MOP, KOP, and DOP receptors, with 1–2 orders of
magnitude lower affinity at NOP (Table 1). No selectivity in
binding between MOP, KOP, and DOP receptors was expected
or seen with this series of compounds; similarly there was no
substantial effect on the affinities of the ligands at MOP, KOP,
and DOP receptors on introduction of a substituent to the aryl
ring of the phenylacetyl group. At NOP receptors, it appears that
a substituent on the ring may be beneficial to affinity with a two-
to four-fold increase in affinity on addition of a single substituent
(compare unsubstituted 7a to substituted analog 7b-7k). When
compared with the parent compound 4, these ligands displayed a
substantial increase in binding affinity toward the NOP receptor,
a small increase in affinity at DOP (two- to eight-fold) and no
change atMOP andKOP. Affinities were almost identical to those
of buprenorphine (1).
The in vitro assay used to determine opioid receptor
functional activity was the [35S]GTPγ S binding stimulation
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SCHEME 1 | Synthesis of 14-O-phenylacetylnaltrexone and analogs. Reagents and conditions: (i) TBDMSiCl, imidazole, DCM, rt; (ii) R-phenylacetic anhydride,
toluene, 125◦C; (iii) MeOH-HCl (6N) 1:1, reflux.
TABLE 1 | Binding affinities of new compounds to human opioid receptor
transfected into CHO cellsa.
Cpd R Ki/nM
NOP MOP DOP KOP
7a H 127 ± 17 0.86 ± 0.18 3.10 ± 0.60 1.14 ± 0.46
7b 4-CH3 36.3 ± 4.2 1.87 ± 0.09 1.70 ± 0.20 1.56 ± 0.28
7c 2-CH3 44.1 ± 3.1 3.59 ± 0.86 1.97 ± 0.19 1.69 ± 1.2
7d 3-CH3 49.9 ± 3.5 1.91 ± 0.51 5.58 ± 0.22 2.80 ± 0.91
7e 3-OCH3 50.1 ± 2.7 1.10 ± 0.08 3.61 ± 0.34 1.44 ± 0.33
7f 4-OCH3 49.8 ± 7.1 1.08 ± 0.33 2.56 ± 0.48 1.90 ± 0.42
7g 3,4-OCH2O- 94.3 ± 28 0.99 ± 0.35 1.25 ± 0.20 1.20 ± 0.42
7h 2-OCH3 62.3 ± 4.9 3.77 ± 0.90 2.12 ± 0.59 3.52 ± 0.90
7i 2-F 69.7 ± 2.4 2.59 ± 1.1 4.07 ± 0.91 4.55 ± 0.70
7j 4-Cl 51.3 ± 14 1.78 ± 0.03 4.95 ± 1.1 3.95 ± 0.59
7k 2-Cl 32.6 ± 2.3 4.66 ± 1.8 3.24 ± 0.15 1.34 ± 0.50
3 – >10K 0.66 ± 0.10 10.7 ± 0.82 1.10 ± 0.22
1 – 77.4 ± 16 1.5 ± 0.8 6.1 ± 0.4 2.5 ± 1.2
aData are the average ± SD from two experiments, each carried out in triplicate.
Tritiated ligands were [3H]DAMGO (MOP), [3H]N/OFQ (NOP), [3H]Cl-DPDPE (DOP), and
[3H]U69593 (KOP).
assay, which, like the binding assays, was performed in human
receptor transfected CHO cells as described previously (31).
Agonist efficacy at these opioid receptors was determined in
comparison to the standard selective agonists N/OFQ (NOP),
DAMGO (MOP), DPDPE (DOP), and U69593 (KOP) (Table 2).
The ligands were predominantly low efficacy agonists at MOP
receptors. 7f, 7g, and 7j were also evaluated as MOP receptor
antagonists with 7f and 7g proving to be very potent competitive
antagonists (pA2 values of 10.58 ± 0.13 and 10.29 ± 0.24,
respectively, Table 3), whereas 7j was non-competitive, as
determined by a Schild analysis with a slope different than
−1. Similar results were obtained at the other receptors with
partial agonism being the standard activity. 7f had sufficiently
low efficacy at KOP, DOP, and NOP receptors to warrant
evaluation as an antagonist at each. Whilst competitive at the
MOP receptor, inhibition was non-competitive at the other
receptors, with IC50 values of 12.4 ± 2.25, 12.2 ± 0.11, 48.1±
14.06, and 5,637 ± 2,242 nM at MOP, KOP, DOP, and NOP,
respectively.
7f was evaluated in CD1 mice using the tail flick assay
with an analgesia instrument (Stoetling) that uses radiant heat.
Methods were as reported previously (27, 31). The overall
ANOVA indicated that there was a significant interaction effect
[F(6, 56) = 3.96, P < 0.05]. The positive control morphine (3
mg/kg) produced the anticipated increase in %MPE at all time
points. At the doses tested (1 and 3 mg/kg) 7f produced low
levels of antinociception, consistent with partial agonist activity
demonstrated in the [35S]GTPγS binding assay. The 1 mg/kg
dose of 7f produced a significant increase in tail flick latency
compared to vehicle controls at the 60- and 120-min time points,
whereas the 3.0 mg/kg dose produced significant antinociception
at the 30- and 120-min time points (Figure 1A). Given that
both doses of 7f produced similar levels of antinociception, we
examined whether the lower dose would alter morphine-induced
analgesia. As evident in Figure 1B, when 7f was given as a
pretreatment to morphine, morphine-induced antinociception
was attenuated at the 30- and 60-min time points (P < 0.05).
DISCUSSION
Substitution at 14-O position of naltrexone (4) has a significant
impact on the pharmacological profile. Lia et al. (40) reported
on a series of 14-O heterocyclic esters of 4 as selective MOP
receptor antagonists with subnanomolar to nanomolar binding
affinities. Similarly we have reported (39) that the predominant
activity of 14-O cinnamoyl esters of 4 was MOP partial
agonism/antagonism both in vitro and in vivo. In contrast, the
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TABLE 2 | Opioid agonist stimulation of [35S]GTPγS binding in recombinant human opioid receptora.
NOP MOP DOP KOP
Cpd EC50/nM % stim EC50/nM % stim EC50/nM % stim EC50/nM % stim
7a 401 ± 161 28.1 ± 4.8 3.8 ± 1.8 31.6 ± 4.2 5.6 ± 0.4 30.5 ± 5.5 1.2 ± 0.6 44.5 ± 13
7b 169 ± 3.4 22.3 ± 1.4 1.6 ± 0.9 34.9 ± 2.0 3.8 ± 1.1 27.0 ± 4.8 6.3 ± 2.2 11.5 ± 2.7
7c 106 ± 32.2 21.1 ± 1.4 2.2 ± 0.2 41.9 ± 1.4 201 ± 59 12.6 ± 3.1 2.9 ± 1.8 86.3 ± 6.5
7d 855 ± 185 59.3 ± 2.4 5.2 ± 2.0 40.1 ± 4.4 21.3 ± 2.2 15.8 ± 0.1 1.0 ± 0.3 46.4 ± 3.6
7e 374 ± 81.6 36.1 ± 0.3 13.3 ± 2.2 11.3 ± 1.3 9.9 ± 0.2 35.7 ± 0.7 1.7 ± 0.4 46.3 ± 8.1
7f 61.8 ± 20.1 8.9 ± 1.0 * 7.8 ± 3.5 59.4 ± 19.6 18.4 ± 1.3 * 6.5 ± 3.3
7g 562 ± 67.5 43.5 ± 9.4 * 12.1 ± 3.7 * ---- 5.4 ± 0.1 41.1 ± 0.9
7h 479 ± 33.3 40.8 ± 5.4 0.5 ± 0.1 37.3 ± 0.7 4.15 ± 1.85 19.2 ± 4.9 1.6 ± 0.3 50.4 ± 6.0
7i 94.1 ± 24.7 14.5 ± 2.9 2.0 ± 0.7 27.9 ± 2.8 * ---- 4.0 ± 2.0 43.8 ± 4.7
7j 298 ± 18.6 18.9 ± 2.7 * 8.2 ± 7.2 2.91 ± 10.6 37.2 ± 0.2 5.4 ± 1.3 37.1 ± 0.2
7k 808 ± 45.8 49.9 ± 0.7 2.4 ± 0.6 39.3 ± 4.7 * ---- 13.9 ± 6.4 31.3 ± 5.6
1 116 ± 88.0 21.0 ± 8.4 10.2 ± 2.2 28.7 ± 1.1 >10,000 ---- >10,000 ----
DAMGO ---- ---- 35.3 ± 0.5 100 ---- ---- ---- ----
Nociceptin 8.1 ± 1.4 100 ---- ---- ---- ---- ----
DPDPE ---- ---- ---- ---- 6.9 ± 0.4 100 ---- ----
U69,593 ---- ---- ---- ---- ---- ---- 78.5 ± 8.8 100
aData are the average ± SD from at least two experiments, each carried out in triplicate.
*Too little stimulation (if <15% an EC50 was not always determined).
N/OFQ, Nociceptin/orphinan FQ.
equivalent phenylpropyl ether was a potent agonist in a battery
of thermal nociceptive assays (38); thus substitution at the 14-
O position of 4 plays a critical role in modulating activity, and
predominantly efficacy, of the ligands at the traditional opioid
receptors MOP, DOP, and KOP. In the current study, this SAR
is further explored and extended to include activity at the NOP
receptor. The new ligands, substituted 14-O-phenylacetyl esters
of 4, were evaluated for binding affinities and efficacies at MOP,
DOP, and KOP, and NOP receptors. Phenylacetyl substitution
at the 14-oxygen had little effect on affinity at MOP, DOP,
and KOP receptors, but did substantially increase the binding
affinity at NOP receptors. Addition of a substituent to the
aryl ring of the phenylacetyl group further increased affinity
for NOP receptors leading to a series of compounds with
binding profiles directly comparable to buprenorphine (1). This
provides support for our hypothesis that the group, in this case
phenylacetyl, attached to the 14-O of 4 can access the same
space as the t-butyl group in 1, leading to moderate affinity
at NOP receptors. The non-competitive binding seen with 7f
and 7j may relate to the increased lipophilicity of these esters
relative to 4. The calculated logPs of 7j (logP 4.41 ± 0.57) and
7f (3.73 ± 0.57) (calculated using ACD/I-lab 2.0) are similar
to those found with the orvinols—a series for which there is
evidence for pseudo-irreversible binding in in vitro bioassays
(25, 41).
Recently the structure of the NOP receptor in complex
with the peptide mimetic C-24 has been determined (42). As
part of the current study, 7c was docked to the binding site
of the crystal structure using GOLD. The docked pose of 7c
that best fit with the known interactions of C-24 with the
protein is illustrated in Figure 2. Key interactions are between
the basic nitrogen and Asp130, while the cyclopropylmethyl
group occupies, but not fully, a lipophilic site accessed by the
dihydroisobenzofuran head group of C-24. Most interestingly,
the phenylacetyl type side chain of 7c extends into the same
region occupied by the pyrolidine ring of C-24 (including the
amino acid residues Gln107, Asp110, Trp116, and Val126) and
perhaps explains the substantial increase in affinity for these
new ligands relative to the parent compound 3, which cannot
access this region. The Schrödinger software was then used to
superimpose buprenorphine on the minimized structure of 7c
in the protein-ligand complex resulting in the same interactions
between the basic nitrogen and the cyclopropylmethyl groupwith
the protein and now with the bulky t-butyl group accessing the
same region as the phenylacetyl group of 7c (Figure 3). We have
shown previously that minor changes to the t-butyl group of
1 can have a significant impact on binding affinity and efficacy
at the NOP receptor (26, 27) and again, the interaction of this
group with the site defined by, amongst other residues, Gln107,
Asp110, Trp116, and Val126 could explain this finding. This
docking pose would also help explain the lack of effect on NOP
affinity on substituting the aromatic A-ring of 1 with halogens
(26) as the A-ring extends into a very large, open region of
the binding pocket, making no close interactions with receptor
residues.
The predominant activity in the [35S]GTPγS assay was of
partial agonism at each of the receptors under study. Thus,
when compared to the parent compound 4, an antagonist,
introduction of the phenylacetyl side chain has increased efficacy
at each receptor. The effect was most pronounced at the
KOP where one compound, 7c, had high efficacy (86% of
the standard) and a number of others fell in the 40–50%
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TABLE 3 | Antagonist activity of selected compounds at the MOP receptor in the
[35S]GTPγS binding assay.
MOP
Compound Ke pA2
7f 0.026 ± 0.008 10.58 ± 0.14
7g 0.051 ± 0.018 10.29 ± 0.24
7j Non-competitive
Schild analysis indicated that compound 7j had a slope significantly different than −1.0.
This indicated non-competitive antagonism and a pA2 could not be determined. In an
inhibition assay it had an IC50 value of 5.9 ± 1.84 nM when inhibiting DAMGO stimulation
of [35S]GTPγS binding. Results represent cumulative data from at least three separate
experiments.
FIGURE 1 | Acute thermal antinociceptive effect of 7f alone (A) or as a
pretreatment to morphine (B), using the mouse tail flick assay (N = 8/group).
Data are mean %MPE (± SEM). *Significant difference from vehicle control;
†
Significant difference from morphine alone (P < 0.05). Behavioral results were
analyzed by use of repeated measures ANOVAs with drug treatment (7f,
morphine) as between group variables and post-injection time (30, 60, and
120min) as the repeated measure followed by Tukey/Kramer post-hoc tests
where appropriate.
range. In this assay, efficacies were somewhat lower at MOP
and lower still at DOP receptors. Some consistent SAR does
emerge, with ortho substitution tending to give the highest
FIGURE 2 | Docking of 7c in the binding site of the NOP receptor. 7c is
shown with cyan carbons. The protein is shown with green carbons apart from
D130 which has purple carbons. For clarity, residues C200, L201, V202, and
T305 are shown as lines rather than sticks. The crystal structure ligand, C-24,
is shown as lines with brown carbons.
efficacy, followed by meta and then para at both MOP and
KOP receptors. A similar trend is observed at NOP receptors,
where the ortho and meta-substituted ligands were typically
higher efficacy than their para substituted equivalents. At MOP
and NOP receptors a number of the new ligands had profiles
somewhat similar to 1, though typically with more selectivity
for MOP. The most substantial difference to 1 was at the
KOP receptor where the potent partial agonism of many
of the current series contrasts with the potent antagonism
characteristic of 1. Compared to the closely related cinnamoyl
esters reported previously (39), these phenylacetyl esters have
similar affinities, but higher efficacies at MOP, DOP, and KOP
receptors (NOP receptor activity was not measured for the
cinnamoyl esters).
The 4-methoxy substituted analog 7f was of interest due to its
good affinity and very low level stimulation of all the receptors in
the [35S]GTPγS assay. Agonists for KOP and DOP receptors have
been, and continue to be, evaluated as potential analgesics either
as selective ligands (43) or dual-acting (44). In an extension of the
argument made earlier for the development of mixed MOP/NOP
agonists, it could be envisaged that ligands displaying low efficacy
at each of the receptors might provide analgesia with very little
in the way of side-effect profile. The low level of antinociception
observed in the mouse tail flick assay and the ability to act as
a morphine antagonist is consistent with this hypothesis and
7f may provide a useful lead in the development of new, safer
analgesics.
CONCLUSION
The hypothesis that introduction of a lipophilic group to
the 14-oxygen of 4 would introduce NOP receptor affinity
has been validated by the present study. Moderate affinity,
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FIGURE 3 | Docking of Buprenorphine (1) in the binding site of the NOP
receptor. 1 is shown with cyan carbons. The protein is shown with green
carbons apart from D130 which has purple carbons. For clarity, residues
C200, L201, V202, and T305 are shown as lines rather than sticks. The crystal
structure ligand, C-24, is shown as lines with brown carbons.
equivalent to that of the orvinol buprenorphine (1), was
seen alongside low efficacy partial agonism, supporting our
belief that the t-butyl group of 1 and the phenylacetyl group
of the current series might access the same region of the
NOP receptor. This is reinforced by docking studies, to the
recently solved crystal structure of the NOP receptor that
provide a rationale for the moderate affinity shown by the
ligands reported here and also, help explain the SAR of close
analogs of 1 (26). As expected, introduction of the 14-O side
chain also raised efficacy relative to 4 at the standard opioid
receptors.
METHODS
Reagents and solvents were purchased from Sigma-Aldrich or
Alfa Aesar and used as received. 1H and 13C NMR spectra
were obtained with a Brucker-400-MHz instrument (1H at 400
MHz, 13C at 100 MHz); δ in ppm, J in Hz with TMS as an
internal standard. ESIMS: microTOF (BRUKER). Microanalysis:
Perkin-Elmer 240C analyzer. Column Chromatography was
performed using pre-packed column in combi flash instrument.
Ligands were tested as their hydrochloride salts, prepared
by adding 5 equivalent of HCl (1N solution in diethyl
ether) in a solution of compound in anhydrous methanol.
All reactions were carried out under an inert atmosphere
of nitrogen unless otherwise indicated. All compounds were
>95% pure.
General Procedure. 14-O-Esterification
To a solution of TBDMS-protected naltrexone (5) (0.4 mmol)
in anhydrous toluene, optionally substituted phenylacetic
anhydride (0.8 mmol), and DMAP (0.04 mmol) were
added and the reaction mixture refluxed for 16 h. After
completion saturated sodium bicarbonate (15mL) was added
and the aqueous layer extracted with EtOAc (3 × 10mL).
Organic layer was washed with water (2 × 20mL), brine
(10mL) and dried over magnesium sulfate and evaporated
in vacuo to obtain crude product which was purified by
flash chromatography using methanol:dichloromethane
(0.5:99.5).
General Procedure. TBDMS Deprotection
The substrate (0.3 g) was dissolved in 6mL (1:1) solution of
methanol:hydrochloric acid (6N) and refluxed for 5 h. The
reaction mixture was cooled to 0
◦
C and neutralized with
saturated aq. sodium bicarbonate. The organic layer was
extracted with ethyl acetate (3 × 20ml), washed with water
(2 × 25mL), brine (25mL), dried over magnesium sulfate and
evaporated to obtained crude product which was purified by flash
chromatography using methanol:dichloromethane:ammonium
hydroxide (2:97.5:0.5).
14β-phenylacetyl-17-cyclopropylmethyl-
7,8-dihydronoroxymorphinone (7a)
White Solid; 1H NMR (CDCl3) δ 0.09–0.12 (2H, m), 0.51–0.54
(2H, m), 0.78–0.83 (1H, m), 1.41–1.45 (1H, m), 1.57 (1H, dt,
J = 3.72 and 14.44Hz), 2.09–2.21 (2H, m), 2.23–2.52 (4H, m),
2.58–2.67 (2H, m), 2.79–2.82 (1H, m), 3.07 (1H, d, J = 18.2 Hz),
3.77 (2H, m), 4.44 (1H, d, J = 5.52 Hz), 4.51 (1H, s), 6.59 (1H, d,
J= 8.0 Hz), 6.72 (1H, d, J= 8.0 Hz), 7.24–7.31 (2H, m), 7.36–7.41
(3H, m); HRMS, m/z for (C28H30NO5) [MH]+, calcd- 460.2124,
found- 460.2103.
14β-(4′-methylphenylacetyl)-17-
cyclopropylmethyl-7,8-
dihydronoroxymorphinone (7b)
White Solid; 1H NMR (CDCl3) δ 0.09–0.12 (2H, m), 0.50–0.54
(2H, m), 0.74–0.80 (1H, m), 1.44–1.48 (1H, m), 1.61 (1H, dt,
J = 3.72 and 14.44Hz), 2.14–2.22 (2H, m), 2.27–2.51 (8H, m),
2.57–2.61 (1H, m), 2.78–2.82 (1H, m), 3.07 (1H, d, J = 18.2 Hz),
3.74–3.76 (2H, m), 4.48 (1H, d, J = 5.52 Hz), 4.53 (1H, s), 6.60
(1H, d, J = 8.0 Hz), 6.72 (1H, d, J = 8.0 Hz), 7.16 (2H, d, J = 8.0
Hz), 7.27 (2H, d, J = 8.0 Hz); HRMS, m/z for (C29H32NO5)
[MH]+, calcd-474.2280, found-474.2329.
14β-(2′-methylphenylacetyl)-17-
cyclopropylmethyl-7,8-
dihydronoroxymorphinone (7c)
White Solid; 1H NMR (CDCl3) δ 0.09–0.14 (2H, m), 0.51–0.55
(2H, m), 0.78–0.84 (1H, m), 1.32–1.35 (1H, m), 1.51 (1H, dt,
J = 3.72 and 14.44Hz), 2.10–2.50 (10H, m), 2.62–2.68 (1H, m),
2.74–2.81 (1H, m), 3.03 (1H, d, J = 18.2 Hz), 3.76–3.88 (2H, m),
4.42 (1H, s), 4.51 (1H, d, J= 5.52 Hz), 5.90 (1H, bd), 6.59 (1H, d,
J= 8.0 Hz), 6.72 (1H, d, J= 8.0 Hz), 7.20–7.23 (3H, m), 7.29–7.33
(1H, m); HRMS, m/z for (C29H32NO5) [MH]+, calcd- 474.2280,
found- 474.2258.
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14β-(3′-methylphenylacetyl)-17-
cyclopropylmethyl-7,8-
dihydronoroxymorphinone (7d)
White Solid; 1H NMR (CDCl3) δ 0.09–0.12 (2H, m), 0.50–0.0.54
(2H, m), 0.70–0.75 (1H, m), 1.45–1.49 (1H, dd, J= 4.00 and 12.1
Hz), 1.59–1.66 (1H, dt, J= 3.72 and 14.44Hz), 2.14–2.31 (2H, m),
2.32–2.40 (8H, m), 2.67 (1H, dd, J = 4.0 and 12.1 Hz), 2.76–2.81
(1H, m), 3.07 (1H, d, J = 18.4 Hz), 3.69 (2H, dd, J = 8.0 and 18.4
Hz), 4.49 (1H, d, J= 4.0 Hz), 4.53 (1H, s), 5.75 (1H, bd), 6.60 (1H,
d, J = 8.0 Hz), 6.73 (1H, d, J = 8.0 Hz), 7.11 (1H, d, J = 6.1 Hz),
7.17 (3H, d, J = 8.1 Hz); HRMS, m/z for (C29H32NO5) [MH]+,
calcd- 474.2280, found- 474.2288.
14β-(3′-methoxyphenylacetyl)-17-
cyclopropylmethyl-7,8-
dihydronoroxymorphinone (7e)
White Solid; 1H NMR (CDCl3) δ 0.09–0.14 (2H, m), 0.50–0.0.54
(2H, m), 0.69–0.74 (1H, m), 1.45–1.49 (1H, dd, J= 4.00 and 12.1
Hz), 1.59–1.66 (1H, dt, J= 3.72 and 14.44Hz), 2.14–2.31 (2H, m),
2.31–2.41 (5H, m), 2.67 (1H, dd, J = 4.0 and 12.1 Hz), 2.76–2.81
(1H, m), 3.07 (1H, d, J = 18.4 Hz), 3.71 (2H, dd, J = 8.0 and 18.4
Hz), 3.83 (3H, s), 4.49 (1H, d, J = 4.0 Hz), 4.54 (1H, s), 5.79 (1H,
bd), 6.60 (1H, d, J = 8.0 Hz), 6.73 (1H, d, J = 8.0 Hz), 6.83 (1H,
dd, J = 4.0 and 8.1 Hz), 6.95–6.99 (2H, m), 7.28–7.30 (1H, m);
HRMS, m/z for (C29H32NO6) [MH]+, calcd- 490.2230, found-
490.2278.
14β-(4′-methoxyphenylacetyl)-17-
cyclopropylmethyl-7,8-
dihydronoroxymorphinone (7f)
White Solid; 1H NMR (CDCl3) δ 0.05–0.08 (2H, m), 0.46–0.50
(2H, m), 0.70–0.73 (1H, m), 1.42–1.45 (1H, m), 1.56 (1H, dt,
J = 3.76 and 14.44Hz), 2.11–2.16 (2H, m), 2.18–2.47 (5H, m),
2.61–2.67 (1H, m), 2.74–2.79 (1H, m), 3.03 (1H, d, J = 18.2 Hz),
3.64–3.73 (2H, m), 3.79 (3H, s), 4.44 (1H, d, J = 5.52 Hz), 4.52
(1H, s), 6.56 (1H, d, J = 8.0 Hz), 6.69 (1H, d, J = 8.0 Hz), 6.85
(2H, d, J = 8.0 Hz), 7.25 (2H, d, J = 8.0 Hz); HRMS, m/z for
(C29H32NO6) [MH]+, calcd- 490.2230, found- 490.2200.
14β-(3′,4′-dioxymethylenephenylacetyl)-17-
cyclopropylmethyl-7,8-
dihydronoroxymorphinone (7g)
White Solid; 1H NMR (CDCl3) δ 0.09–0.14 (2H, m), 0.51–0.54
(2H, m), 0.89–0.95 (1H, m), 1.46–1.51 (1H, m), 1.57 (1H, dt,
J = 3.76 and 14.44Hz), 2.11–2.31 (3H, m), 2.36–2.46 (4H, m),
2.65–2.72 (1H, m), 2.76–2.82 (1H, m), 3.08 (1H, d, J = 18.2 Hz),
3.68–3.72 (2H, m), 4.49 (1H, d, J = 5.52 Hz), 4.58 (1H, s), 5.50
(1H, bd), 5.97 (2H, s), 6.61 (1H, d, J = 8.0 Hz), 6.73 (1H, d,
J = 8.0 Hz), 6.79–6.82 (2H, m), 6.92 (1H, s); HRMS, m/z for
(C29H30NO7) [MH]+, calcd- 504.2022, found- 504.2069.
14β-(2′-methoxyphenylacetyl)-17-
cyclopropylmethyl-7,8-
dihydronoroxymorphinone (7h)
White Solid; 1H NMR (CDCl3) δ 0.08–0.11 (2H, m), 0.49–0.52
(2H, m), 0.78–0.84 (1H, m), 1.32–1.35 (1H, m), 1.51 (1H, dt,
J = 3.72 and 14.44Hz), 2.10–2.45 (6H, m), 2.55–2.65 (2H, m),
2.74–2.81 (1H, m), 3.03 (1H, d, J = 18.2 Hz), 3.76 (2H, m), 3.81
(3H, s), 4.34 (1H, s), 4.43 (1H, d, J = 5.52 Hz), 5.61 (1H, bd),
6.55 (1H, d, J = 8.0 Hz), 6.68 (1H, d, J = 8.0 Hz), 6.89 (1H, d,
J = 8.0 Hz), 6.93 (1H, m), 7.24–7.28 (2H, m); HRMS, m/z for
(C29H32NO6) [MH]+, calcd- 490.2230, found- 490.2228.
14β-(2′-fluorophenylacetyl)-17-
cyclopropylmethyl-7,8-
dihydronoroxymorphinone (7i)
White Solid; 1H NMR (CDCl3) δ 0.06–0.09 (2H, m), 0.48–0.0.51
(2H, m), 0.71–0.75 (1H, m), 1.33–1.36 (1H, m), 1.56–1.64 (1H,
dt, J = 3.72 and 14.44Hz), 2.04–2.42 (6H, m), 2.46–2.62 (2H, m),
2.76–2.80 (1H, m), 3.07 (1H, d, J = 18.4 Hz), 3.72 (2H, m), 4.42
(1H, d, J= 4.0 Hz), 4.44 (1H, s), 5.65 (1H, bd), 6.56 (1H, d, J= 8.0
Hz), 6.68 (1H, d, J = 8.0 Hz), 7.08–7.14 (2H, m), 7.25–7.29 (1H,
m) 7.35–7.37 (1H, m); HRMS, m/z for (C28H29FNO5) [MH]+,
calcd- 478.2030, found- 478.2073.
14β-(4′-chlorophenylacetyl)-17-
cyclopropylmethyl-7,8-
dihydronoroxymorphinone (7j)
White Solid; 1H NMR (CDCl3) δ 0.04–0.10 (2H, m), 0.47–0.50
(2H, m), 0.65–0.69 (1H, m), 1.43–1.46 (1H, m), 1.59 (1H, dt,
J = 3.72 and 14.44Hz), 2.08–2.16 (1H, m), 2.21–2.34 (4H, m),
2.39–2.48 (2H, m), 2.62–2.65 (1H, m), 2.74–2.81 (1H, m), 3.04
(1H, d, J = 18.2 Hz), 3.72–3.74 (2H, m), 4.43 (1H, d, J = 5.52
Hz), 4.53 (1H, s), 6.56 (1H, d, J = 8.0 Hz), 6.70 (1H, d, J = 8.0
Hz), 7.29–7.31 (4H, m); HRMS, m/z for (C28H29ClNO5) [MH]+,
calcd- 494.1734, found- 494.1734.
14β-(2′-chlorophenylacetyl)-17-
cyclopropylmethyl-7,8-
dihydronoroxymorphinone (7k)
White Solid; 1H NMR (CDCl3) δ 0.08–0.10 (2H, m), 0.49–0.53
(2H, m), 0.76–0.81 (1H, m), 1.30–1.33 (1H, m), 1.56 (1H, dt,
J = 3.72 and 14.44Hz), 2.04–2.09 (2H, m), 2.25–2.32 (3H, m),
2.41–2.46 (1H, m), 2.53–2.59 (2H, m), 2.76–2.81 (1H, m), 3.03
(1H, d, J = 18.2 Hz), 3.90 (2H, m), 4.41 (1H, d, J = 4.0 Hz),
4.43 (1H, s), 5.48 (1H, bd), 6.55 (1H, d, J = 8.0 Hz), 6.68 (1H,
d, J= 8.0 Hz), 7.24–7.26 (2H, m), 7.40–7.43 (2H, m); HRMS, m/z
for (C28H29ClNO5) [MH]+, calcd- 494.1734, found- 494.1729.
Molecular Modeling Methods
The 4EA3 crystal structure (42) of NOP was the starting
point. The structure was run through the Protein Preparation
Wizard in the Schrödinger software suite running under Maestro
version 9.3.023. Buprenorphine (1) and 7c were built and
minimized using the same software. Both ligands were docked
into the binding site using GOLD. The docked pose of 7c
that seemed to best fit with the known interactions of the
ligand with the protein was subjected to 1,000 rounds of
minimization using the Schrödinger MacroModel software with
the constraint that the ligand nitrogen be 2.8 Å from the
nearest acidic oxygen of D130. GOLD failed to bind 1 with
a sensible pose so the Schrödinger software was used to
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superimpose 1 on the minimized structure of 7c in the protein-
ligand complex. The protein-1 complex was then subjected to
1,000 rounds of minimisation. Figures were prepared using
PyMOL.
In vitro Characterization
Cell culture
All receptors were individually expressed in CHO cells stably
transfected with human receptor cDNA, The cells were
grown in Dulbecco’s Modified Eagle Medium (DMEM)
with 10% fetal bovine serum, in the presence of 0.4
mg/ml G418 and 0.1% penicillin/streptomycin, in 100-
mm polystyrene culture dishes. For binding assays, the
cells were scraped off the plate at confluence. Receptor
expression levels were 1.2, 1.6, 1.8, and 3.7 pmol per
mg protein for the NOP, MOP, KOP, and DOP receptors,
respectively.
Receptor binding
Binding to cell membranes was conducted in a 96-well format,
as described previously (45, 46). Briefly, cells were removed
from the plates, homogenized in 50mM Tris pH 7.5, using
a Polytron homogenizer, then centrifuged once and washed
by an additional centrifugation at 27,000 × g for 15min.
The final pellet was re suspended in Tris, and the suspension
incubated with [3H]DAMGO (51 Ci/mmol, 1.6 nM), [3H]Cl-
DPDPE (42 Ci/mmol, 1.4 nM), [3H]U69593 (41.7 Ci/mmol,
1.9 nM), or [3H]N/OFQ (120 Ci/mmol, 0.2 nM) for binding
to, MOP, DOP, KOP, and NOP receptors, respectively. Non-
specific binding was determined with 1µM of unlabeled
DAMGO ([D-Ala2, N-MePhe4, Gly-ol]-enkephalin), DPDPE
([D-Pen2,D-Pen5]Enkephalin), ethylketocyclazocine, and
N/OFQ, respectively. Samples were incubated for 60min at
25◦C in a total volume of 1.0ml, with 15 µg protein per well.
The reaction was terminated by filtration using a Tomtec
96 harvester (Orange, CT) through glass fiber filters and
radioactivity was counted on a Pharmacia Biotech beta-plate
liquid scintillation counter (Piscataway, NJ). IC50 values were
calculated using Graphpad/Prism (ISI, San Diego, CA) and
Ki values were determined by the method of Cheng and
Prusoff (47).
[35S]GTPγ S binding
[35S]GTPγS binding was conducted basically as described by
Traynor and Nahorski (48). Cells were scraped from tissue
culture dishes into 20mM Hepes, 1mM EDTA, then centrifuged
at 500x g for 10min. Cells were resuspended in this buffer and
homogenized using a Polytron Homogenizer. The homogenate
was centrifuged at 27,000 × g for 15min, and the pellet re
suspended in Buffer A, containing: 20mMHepes, 10mMMgCl2,
100mM NaCl, pH 7.4. The suspension was re centrifuged at
27,000 × g and suspended once more in Buffer A. For the
binding assay, membranes (8–15 µg protein) were incubated
with [35S]GTPγS (50 pM), GDP (10µM), and the appropriate
compound, in a total volume of 1.0ml, for 60min at 25◦C.
Samples were filtered over glass fiber filters and counted
as described for the binding assays. Statistical analysis was
conducted using the program Prism. For the antagonist assay,
various concentrations of 7f, 7g, and 7j were incubated in
the presence of 100 nM N/OFQ, or 1µM DAMGO, DPDPE
or U69593 to determine antagonist potency at NOP, MOP,
DOP, and KOP receptors, respectively. Schild analysis was also
conducted at MOP receptors using various concentrations of
the inhibitor in the present of a full DAMGO dose response
curve.
In vivo Testing
Animals
Male ICR mice weighing 25–30 g at the start of the experiment
were used. Animals were group-housed (N = 10/cage) under
standard laboratory conditions using nestlets as environmental
enrichment in their cages and were kept on a 12:12-hr day/night
cycle (lights on at 7:00 a.m.). Testing was conducted during
the animals’ light cycle between 9 a.m. and 2 p.m. Animals
were handled for 3–4 days before the experiments were
conducted. On behavioral test days, animals were transported
to the testing room and acclimated to the environment for
1 h. Mice were maintained in accordance with the guidelines
of SRI International and of the Guidelines for the Care and
Use of Mammals in Neuroscience and Behavioral Research
(49). Prior to any in vivo testing, approval for the behavioral
protocols was obtained from the institutional ACUC of SRI
International.
Drugs
7f was dissolved in 1–2% Dulbecco’s modified Eagle’s medium
and 0.5% aqueous hydroxypropyl cellulose. Morphine
hydrochloride (Eli Lilly & Co., Indianapolis, IN) was dissolved
in water. Drugs were injected subcutaneously (s.c.) in a volume
of 0.1 ml/30 g. Controls received 0.1 ml/30 g of the appropriate
vehicle.
Assessment of acute thermal nociception
Tail-flick assay. Acute nociception was assessed using the tail
flick assay with an analgesia instrument (Stoelting) that uses
radiant heat. This instrument is equipped with an automatic
quantification of tail flick latency, and a 15 s cutoff to prevent
damage to the animal’s tail. During testing, the focused beam of
light was applied to the lower half of the animal’s tail, and tail flick
latency was recorded.
Baseline values for tail flick latency were determined before
drug administration in each animal. The mean basal tail flick
latency was 5.39 ± 0.09 SEM. After baseline measures, animals
received a subcutaneous injection of their assigned dose of
drug(s) and were tested for tail-flick latencies at 30, 60, and
120min following the last drug injection. Controls received
vehicle prior to testing.
Drug regimen. In the first series of experiments, animals
(N = 8/group) received injections of 7f (1 and 3 mg/kg s.c.) or
morphine (3 mg/kg). Given that both 1 and 3 mg/kg 7f produced
similar levels of antinociception, we chose to examine the effects
of 1 mg/kg 7f given as a pretreatment to morphine. In these
experiments, animals received 1 mg/kg 7f or vehicle and 10min
later received an injection of morphine. A group of animals
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served as vehicle controls. Testing was conducted as described
above.
Statistical analyses. Antinociception (% maximum potential
effect; % MPE) was quantified by the following formula:
% MPE = 100[(test latency–baseline latency)/(15–baseline
latency)]. If the animal did not respond before the 15-s
cutoff, the animal was assigned a score of 100%. Behavioral
results were analyzed by use of repeated measures ANOVAs
with drug treatment (7f, morphine) as between group
variables and post-injection time (30, 60, and 120min) as
the repeated measure followed by Tukey/Kramer post-hoc
tests where appropriate. The level of significance was set at
P = 0.05.
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